Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for PEGVISOMANT
- Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
- Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
- Strict IGF-1 Control in Acromegaly
- Pasireotide LAR and Pegvisomant Study in Acromegaly
- Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting
- Phase II Study With ITF2984 in Acromegalic Patients
- Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes
- A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects
- Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency
- Effect of DPP4 Inhibition on Growth Hormone Secretion
- Acromegaly Combination Treatment Study
- Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
- Tissue Biomarker for Pegvisomant Action
- Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
- Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
- The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons
- Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
- Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
- Acute Application of Pegvisomant and Octreotide in Acromegaly
- Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
- Growth Hormone Signaling in Vivo in Humans
- Effect of Pegvisomant on GH/IGF-I Relationship in GHD
- Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
- Canadian Pegvisomant Compassionate Study In Acromegalic Patients
- Long Term Study With B2036-PEG
- A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
- Pegvisomant And Sandostatin LAR Combination Study
- A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
Clinical trials list
click for details